



Cxbladder Bulletin: November 2025

Dear Customers and Friends of Cxbladder,

Welcome to the November 2025 edition of the Cxbladder Bulletin. In this issue:

- DRIVE publication provides clinical validation of Cxbladder Triage Plus
- Urology Times reviews DRIVE study
- Watch Now: Webinars From the Grand Rounds in Urology Microhematuria Hub
 - **The Utility of Cxbladder Triage In Microhematuria Evaluation:** Expert Discussion featuring Dr. Evan Goldfischer, Dr. Kristen Scarpato, Dr. Ronald Loo, and Pacific Edge Senior Medical Director Dr. Jay Jhaveri
 - **The 2025 AUA/ SUFU Microhematuria Guideline:** Dr. Jason Hafron reviews
 - **Industry Perspective: Cxbladder Triage AUA/ SUFU Guideline Inclusion:** Grand Rounds host Diane Newman speaks with Dr. Jay Jhaveri

DRIVE Publication Provides Clinical Validation of Triage Plus

We're pleased to confirm that our DRIVE Study — which demonstrates the clinical validity of Cxbladder Triage Plus in a US veterans population — has been published in the Journal of Urologic Oncology¹.

Cxbladder Triage Plus is a next generation Cxbladder test that employs a novel combination of mRNA and DNA markers to extend best in class performance. Triage Plus enhances the identification and prioritization of patients who require immediate care, while deferring those with a low probability of UC who do not stand to benefit from cystoscopy. As a single test for both gross and microhematuria which requires a urine sample only - no information on additional patient factors is required - Triage Plus is designed to deliver superior performance over first generation Cxbladder tests while simplifying the ordering process.

The DRIVE Study evaluated the performance of Cxbladder Triage Plus when compared to cystoscopy combined with histopathologic confirmation of urothelial cancer. It confirmed the performance characteristics of Triage Plus established via the Analytical Validation publication (Harvey et al. 2025²) in a patient population independent of the development dataset utilized in the proof-of-concept study by Lotan et al. in 2023³.

The authors of the DRIVE study concluded: “Cxbladder Triage Plus demonstrated clinical validity in this veterans population with gross hematuria or microhematuria, with high sensitivity and specificity. These findings indicate that Triage Plus may be safely used to rule out or detect [urothelial cancer] in patients with hematuria.”

Please contact us at info@cxbladder.com to discuss the availability of Cxbladder Triage Plus in your region.


Figure 1: Results from the DRIVE study. Triage Plus demonstrated a higher specificity and sensitivity than first generation Cxbladder assays.

Test	Sensitivity	Specificity	Negative Predictive Value	Positive Predictive Value	Test Negative Rate
Cxbladder Triage	93%	38%	98.5%	11%	35%
Cxbladder Triage Plus Intermediate risk patients	94%	77%	99.3%	26%	71%
Cxbladder Triage Plus High risk patients		95%		51%	90%

Urology Times Reviews DRIVE Study

Leading industry platform Urology Times reviews the DRIVE study, now published in Urologic Oncology¹.

Click [here](#) to read the article or click the image below.



Urology Times[®]

Study validates diagnostic performance of Cxbladder Triage Plus Test

News | Articles


Grand Rounds in Urology Launches Microhematuria Hub

Earlier this year a major amendment to the AUA/ SUFU Microhematuria

Guideline⁴ included language supporting the use of urine-based tumor marker (UBTM) tests in appropriately counselled intermediate risk patients. Cxbladder Triage, a UBTM test optimized for risk stratification, was included with supporting Grade A evidence from a randomized controlled trial (the STRATA study⁵).

In November, Grand Rounds in Urology, an authoritative source for educational webinars, podcasts, and articles alongside industry news and information on key meetings, launched a Microhematuria hub designed to provide guidance and further analysis of the Guideline update.

Click [here](#) or the image below to review the Microhematuria Hub



Featured webinars on the Grand Rounds Microhematuria Hub include:

- **The Utility of Cxbladder Triage in Microhematuria Evaluation:** Expert discussion featuring Dr. Evan Goldfischer, Dr. Kristen Scarpato, Dr. Ronald Loo, and Pacific Edge Senior Medical Director Dr. Jay Jhaveri. Click [here](#) to view the webinar.
- **The 2025 AUA/ SUFU Microhematuria Guideline:** A review by Dr. Jason

Hafron. Click [here](#) to view the webinar.

- **Industry Perspective - Cxbladder Triage AUA/SUFU Microhematuria Guideline Inclusion:** Dr. Jay Jhaveri discusses the implications with Grand Rounds' host Diane Newman. Click [here](#) to view the webinar.

Contact Us

Email us at info@cxbladder.com or speak to your local Cxbladder representative.



¹ Savage et al. (2025) Diagnostic performance of Cxbladder Triage Plus for the identification and stratification of patients at risk for urothelial carcinoma: The multicenter, prospective, observational DRIVE study. Urologic oncology, S1078-1439(25)00405-3. Advance online publication.

<https://doi.org/10.1016/j.urolonc.2025.10.008>

² Harvey et al. (2025) Analytical Validation of the Cxbladder® Triage Plus Assay for Risk Stratification of Hematuria Patients for Urothelial Carcinoma. Diagnostics. 2025; 15(14):1739.

<https://doi.org/10.3390/diagnostics15141739>.

³ Lotan et al., (2023). Urinary Analysis of FGFR3 and TERT Gene Mutations Enhances Performance of Cxbladder Tests and Improves Patient Risk Stratification. The Journal of Urology, 10-1097.

⁴ Barocas et al. (2025) Updates to Microhematuria: AUA/SUFU Guideline (2025). The Journal of urology, 213(5), 547–557. <https://doi.org/10.1097/JU.0000000000004490>.

⁵ Lotan et al. (2024) A Multicenter Prospective Randomized Controlled Trial Comparing Cxbladder Triage to Cystoscopy in Patients With Microhematuria. The Safe Testing of Risk for Asymptomatic Micro 9016, New Zealand